These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 7526016

  • 1. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K, Okura H.
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C, Mohn-Staudner A, Vetter H, Kokron O, Baumgartner G, Scheiner W, Zwick H, Koderhold G, Alth G, Dudczak R.
    Wien Klin Wochenschr; 1996 Oct; 108(15):467-72. PubMed ID: 8806188
    [Abstract] [Full Text] [Related]

  • 3. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P, Riantawan P, Lebnak P, Getngern P.
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [Abstract] [Full Text] [Related]

  • 4. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Apr; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 5. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
    Berzinec P, Zuffová H, Letkovicová M, Arpásová M.
    Neoplasma; 1996 Apr; 43(3):159-61. PubMed ID: 8841502
    [Abstract] [Full Text] [Related]

  • 6. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Apr; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 7. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
    Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D, Jordanoglou J.
    Anticancer Res; 1996 Dec; 16(4A):2101-4. PubMed ID: 8712750
    [Abstract] [Full Text] [Related]

  • 9. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
    Zissimopoulos A, Stellos K, Permenopoulou V, Petrakis G, Theodorakopoulos P, Baziotis N, Thalassinos N.
    Hell J Nucl Med; 2007 Dec; 10(1):62-6. PubMed ID: 17450257
    [Abstract] [Full Text] [Related]

  • 10. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E.
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [Abstract] [Full Text] [Related]

  • 11. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
    Pavićević R, Milicić J, Bubanović G, Supe S.
    Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
    [Abstract] [Full Text] [Related]

  • 12. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
    Satoh H, Yagyu H, Sumi M, Ishikawa H, Hamada M, Suyama T, Naitoh T, Inoue M, Saitoh T, Uchida Y.
    Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
    [Abstract] [Full Text] [Related]

  • 13. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S.
    Cancer; 1996 Apr 01; 77(7):1274-7. PubMed ID: 8608502
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
    Karnak D, Ulubay G, Kayacan O, Beder S, Ibis E, Oflaz G.
    Lung; 2001 Apr 01; 179(1):57-65. PubMed ID: 11479694
    [Abstract] [Full Text] [Related]

  • 15. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C, Sliutz G, Mustafa G, Bieglmayr C, Koelbl H, Reinthaller A, Gitsch G.
    Gynecol Oncol; 1995 Mar 01; 56(3):402-5. PubMed ID: 7535720
    [Abstract] [Full Text] [Related]

  • 16. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T.
    Cancer; 1997 May 01; 79(9):1647-55. PubMed ID: 9128978
    [Abstract] [Full Text] [Related]

  • 17. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep 01; 39(5):832-5. PubMed ID: 19024326
    [Abstract] [Full Text] [Related]

  • 18. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM, Seiffert UB, Siekmeier R, Kirsten R.
    Med Klin (Munich); 1995 Jan 15; 90(1):23-6. PubMed ID: 7533887
    [Abstract] [Full Text] [Related]

  • 19. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
    Zhang S, Ma Y, Yang X.
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 May 15; 22(5):271-3. PubMed ID: 11775851
    [Abstract] [Full Text] [Related]

  • 20. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
    Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghé B, Roncari G.
    Q J Nucl Med; 1995 Dec 15; 39(4):285-9. PubMed ID: 8624791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.